- Home
- SYRE vs INVA Comparison
SYRE vs INVA Comparison
Compare SYRE & INVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYRE
- INVA
- Stock Information
- Founded
- SYRE 2013
- INVA 1996
- Country
- SYRE United States
- INVA United States
- Employees
- SYRE N/A
- INVA N/A
- Industry
- SYRE Biotechnology: Pharmaceutical Preparations
- INVA Biotechnology: Pharmaceutical Preparations
- Sector
- SYRE Health Care
- INVA Health Care
- Exchange
- SYRE Nasdaq
- INVA Nasdaq
- Market Cap
- SYRE 1.1B
- INVA 1.2B
- IPO Year
- SYRE 2016
- INVA 2004
- Fundamental
- Price
- SYRE $17.38
- INVA $20.16
- Analyst Decision
- SYRE Buy
- INVA Strong Buy
- Analyst Count
- SYRE 5
- INVA 4
- Target Price
- SYRE $55.00
- INVA $40.25
- AVG Volume (30 Days)
- SYRE 490.8K
- INVA 821.7K
- Earning Date
- SYRE 08-05-2025
- INVA 08-06-2025
- Dividend Yield
- SYRE N/A
- INVA N/A
- EPS Growth
- SYRE N/A
- INVA N/A
- EPS
- SYRE N/A
- INVA 0.53
- Revenue
- SYRE N/A
- INVA $370,229,000.00
- Revenue This Year
- SYRE N/A
- INVA $4.32
- Revenue Next Year
- SYRE N/A
- INVA $9.24
- P/E Ratio
- SYRE N/A
- INVA $37.67
- Revenue Growth
- SYRE N/A
- INVA 12.02
- 52 Week Low
- SYRE $10.91
- INVA $16.67
- 52 Week High
- SYRE $40.26
- INVA $22.00
- Technical
- Relative Strength Index (RSI)
- SYRE 57.01
- INVA 56.46
- Support Level
- SYRE $15.73
- INVA $19.86
- Resistance Level
- SYRE $17.42
- INVA $21.13
- Average True Range (ATR)
- SYRE 0.89
- INVA 0.55
- MACD
- SYRE 0.07
- INVA 0.11
- Stochastic Oscillator
- SYRE 86.50
- INVA 69.91
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
About INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.